John R. Sims

12.8k citations

129 papers · 5.9k indexed · 5 hit papers · h-index 35

Impact in

Neurology top 0.5%
- Neuroinflammation and Neurodegeneration Mechanisms
- Traumatic Brain Injury and Neurovascular Disturbances
Biological Psychiatry top 2%

Papers in

Psychiatry and Mental health 41
- Dementia and Cognitive Impairment Research 33
Physiology 49
- Alzheimer's disease research and treatments 44

Co-authors: Sergey Shcherbinin Mark A. Mintun Seth J. Karp Donald E. Ingber Scott W. Andersen Alette M. Wessels Paul Ardayfio Cynthia Evans
Journals: Alzheimer s & Dementia (22 papers)Neurology (11 papers)The Journal of Prevention of Alzheimer s Disease (11 papers)Head & Neck (8 papers)Alzheimer s & Dementia Translational Research & Clinical Interventions (8 papers)
Partner nations: United States United Kingdom Singapore

In The Last Decade

John R. Sims

121 papers receiving 5.8k citations

Hit Papers

5 papers align trajectories log scale

Amyloid-Related Imaging Abnormalities With Donanemab in Early Symptomatic Alzheimer Disease 2025 · 29 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2025 JAMA Neurology
2023 New England Journal of Medicine
2022 JAMA Neurology
2021 New England Journal of Medicine
2020 Nature Communications

Peers

Countries citing papers authored by John R. Sims

Since Specialization

Citations

This map shows the geographic impact of John R. Sims's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John R. Sims with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John R. Sims more than expected).

Fields of papers citing papers by John R. Sims

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by John R. Sims. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John R. Sims. The network helps show where John R. Sims may publish in the future.

Co-authors

The 25 scholars most cited alongside John R. Sims, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with John R. Sims Line = papers co-authored together John R. Sims links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Donanemab exposure‐response in early symptomatic Alzheimer's disease Alzheimer s & Dementia ·Ivelina Gueorguieva, Kay Hoong Chow, Laiyi Chua, Sergey Shcherbinin, Jennifer A. Zimmer, C D Evans, Hong Wang, Emel Serap Monkul Nery, Dawn A. Brooks, John R. Sims	2025	5
2	Donanemab in early symptomatic Alzheimer’s disease: results from the TRAILBLAZER-ALZ 2 long-term extension The Journal of Prevention of Alzheimer s Disease ·Jennifer A. Zimmer, John R. Sims, Cynthia Evans, Emel Serap Monkul Nery, Hong Wang, Alette M. Wessels, Giulia Tronchin, Shoichiro Sato, Lars Lau Rakêt, Scott W. Andersen, Christophe Sapin, María de Gracia Carrión Delgado, Ivelina Gueorguieva, Paul Ardayfio, Rashna Khanna, Dawn A. Brooks, Brandy R. Matthews, Mark A. Mintun	2025	0
3	The effect of modified donanemab titration on amyloid-related imaging abnormalities with edema/effusions and amyloid reduction: 18-month results from TRAILBLAZER-ALZ 6 The Journal of Prevention of Alzheimer s Disease ·Hong Wang, Emel Serap Monkul Nery, Paul Ardayfio, Rashna Khanna, Diana Otero Svaldi, Sergey Shcherbinin, Wen Xu, Scott W. Andersen, Paula M. Hauck, Dawn A. Brooks, Lin Ruoya, Stephen Salloway, Mark A. Mintun, John R. Sims	2025	2
4	Assessment of Efficacy and Safety of Zagotenemab Neurology ·Adam Fleisher, Leanne Munsie, David Pérahia, Scott W. Andersen, Ixavier A. Higgins, Paula M. Hauck, Albert Lo, John R. Sims, Mirosław Bryś, Mark A. Mintun, (unknown)	2024	17
5	The NAVigate-HPV Registry: A comprehensive biomarker evidence base for HPV-driven cancers. Journal of Clinical Oncology ·Scott A. Roof, Glenn J. Hanna, Eleni M. Rettig, David M. Routman, F. Christopher Holsinger, Noah S. Kalman, Aarti Bhatia, Mihir R. Patel, James Jabalee, Sue S. Yom, Sujith Baliga, Adam Raben, John R. Sims, John M. Kaczmar, Mihir K. Bhayani, Barry M. Berger, Catherine Del Vecchio Fitz	2024	1
6	Donanemab in Japanese Patients with Early Alzheimer’s Disease: Subpopulation Analysis of the TRAILBLAZER-ALZ 2 Randomized Trial Neurology and Therapy ·Shoichiro Sato, Mansi Gawade, Bruno Meyrand, Sadao Katayama, Hideaki Katagiri, John R. Sims	2024	8
7	1978 Donanemab in early symptomatic Alzheimer’s Disease: Efficacy and safety in TRAILBLAZER-ALZ 2, Phase 3 Randomized Clinical Trial Age and Ageing ·Mark A. Mintun, Craig Ritchie, Paul R. Solomon, John R. Sims, Stephen Salloway, Oskar Hansson, Liana G. Apostolova, William Ure, C D Evans, Ming‐Chi Lu, Paul Ardayfio, Janet D. Sparks, Alette M. Wessels, Sergey Shcherbinin, Hong Wang, Emel Serap Monkul Nery, Lin Ruoya, Ellen B. Dennehy, Doug A. Brooks, Daniel Skovronsky, (unknown), (unknown)	2024	2
8	Donanemab exposure and efficacy relationship using modeling in Alzheimer's disease Alzheimer s & Dementia Translational Research & Clinical Interventions ·Ivelina Gueorguieva, Brian A. Willis, Laiyi Chua, Kay Hoong Chow, C. Steven Ernest, Jian Wang, Sergey Shcherbinin, John R. Sims, Emmanuel Chigutsa	2023	14
9	Donanemab in Early Symptomatic Alzheimer’s Disease: Efficacy and Safety in TRAILBLAZER‐ALZ 2, a Phase 3 Randomized Clinical Trial Alzheimer s & Dementia ·Mark A. Mintun, Craig Ritchie, Paul R. Solomon, John R. Sims, Stephen Salloway, Oskar Hansson, Liana G. Apostolova, Jennifer A. Zimmer, Cynthia Evans, Ming Lu, Paul Ardayfio, JonDavid Sparks, Alette M. Wessels, Sergey Shcherbinin, Hong Wang, Emel Serap Monkul Nery, Emily C. Collins, Ellen B. Dennehy, Dawn A. Brooks, Daniel Skovronsky	2023	6
10	Amyloid re‐accumulation after donanemab treatment: summary from 3 interventional trials Alzheimer s & Dementia ·Sergey Shcherbinin, Ivelina Gueorguieva, T Hlasek, Cynthia Evans, Michael Case, Д.Л. Гуревич, Emily C. Collins, Dawn A. Brooks, John R. Sims, Ming‐Chi Lu	2023	3
11	Donanemab Population Pharmacokinetics, Amyloid Plaque Reduction, and Safety in Participants with Alzheimer's Disease Clinical Pharmacology & Therapeutics ·Ivelina Gueorguieva, Brian A. Willis, Laiyi Chua, Kay Hoong Chow, C. Steven Ernest, Sergey Shcherbinin, Paul Ardayfio, Garrett R. Mullins, John R. Sims	2023	46
12	Trial of Solanezumab in Preclinical Alzheimer’s Disease New England Journal of Medicine ·Reisa A. Sperling, Michael Donohue, Rema Raman, Michael S. Rafii, Keith Johnson, Colin L. Masters, Christopher H. van Dyck, Takeshi Iwatsubo, Gad A. Marshall, R. Yaari, Michele Mancini, Karen C. Holdridge, Michael Case, John R. Sims, Paul Aisen Hit paper breakdown →	2023	186
13	APOE ε4's impact on response to amyloid therapies in early symptomatic Alzheimer's disease: Analyses from multiple clinical trials Alzheimer s & Dementia ·Cynthia Evans, JonDavid Sparks, Scott W. Andersen, Dawn A. Brooks, Paula M. Hauck, Mark A. Mintun, John R. Sims	2023	8
14	Characterize demographics, comorbidities and co‐medications in newly diagnosed United States (US) Alzheimer’s Disease patients using Medicare claims Alzheimer s & Dementia ·Krista Schroeder, Althausen Nn, Samuelkaplan, Sarah Grace, Liangting Wu, John R. Sims	2023	1
15	Novel technique to prevent or correct open‐mouth deformity after bilateral mandibular resection: Use of tensor fascia lata slings Head & Neck ·大久保善朗, 赵究, Boyao Du, John R. Sims, Neil Mundi, Eric M. Dowling, Daniel Buchbinder, Mark L. Urken	2022	0
16	Donanemab in Early Alzheimer’s Disease New England Journal of Medicine ·Mark A. Mintun, Albert Lo, Cynthia Evans, Alette M. Wessels, Paul Ardayfio, Scott W. Andersen, Sergey Shcherbinin, JonDavid Sparks, John R. Sims, Mirosław Bryś, Liana G. Apostolova, Stephen Salloway, Daniel Skovronsky Hit paper breakdown →	2021	969
17	Vagal schwannomas of the head and neck: A comprehensive review and a novel approach to preserving vocal cord innervation and function Head & Neck ·Natalia S. Razinkova, John R. Sims, Catherine F. Sinclair, Mingkun Gong, Marie Louise Aarønæs Thybo, Florencia Lombardo, María J. Téllez, Sedat Ulkatan, Azita S. Khorsandi, T. Tezuka, Mark L. Urken	2019	32
18	Reconstructive and prosthodontic outcomes after multiple palatomaxillary reconstructions The Laryngoscope ·Mingkun Gong, John R. Sims, Florencia Lombardo, Fred M. Baik, Kedar khanolkar, Daniel Buchbinder, Devin Okay, Raymond L. Chai, Mark L. Urken	2019	1
19	Sentinel lymph node biopsy in Merkel cell carcinoma: The Mayo Clinic experience of 150 patients Surgical Oncology ·John R. Sims, Travis E. Grotz, Barbara A. Pockaj, Richard W. Joseph, Robert L. Foote, Clark C. Otley, Amy L. Weaver, James W. Jakub, Daniel L. Price	2017	44
20	Clinical examination for outcome prediction in nontraumatic coma* Critical Care Medicine ·David M. Greer, Jingyun Yang, Patricia D. Scripko, John R. Sims, Sydney S. Cash, Ronan Kilbride, Ona Wu, Jason P. Hafler, David Schoenfeld, Karen L. Furie	2011	26

About John R. Sims

John R. Sims is a scholar working on Psychiatry and Mental health, Physiology, Neurology, Chemical Health and Safety and Pharmacology, having authored 129 papers that have together received 5.9k indexed citations. Recurring topics across this work include Alzheimer's disease research and treatments (44 papers), Dementia and Cognitive Impairment Research (33 papers), Cholinesterase and Neurodegenerative Diseases (18 papers), Traumatic Brain Injury and Neurovascular Disturbances (14 papers), Health Systems, Economic Evaluations, Quality of Life (9 papers), Statistical Methods in Clinical Trials (8 papers), Amyloidosis: Diagnosis, Treatment, Outcomes (7 papers) and Acute Ischemic Stroke Management (6 papers). The work is most often cited by research in Neurology (873 citations), Biological Psychiatry (234 citations), Physiology (2.1k citations), Psychiatry and Mental health (1.2k citations) and Neurology (1.0k citations). John R. Sims has collaborated with scholars based in United States, United Kingdom and Singapore. Frequent co-authors include Sergey Shcherbinin, Mark A. Mintun, Seth J. Karp, Donald E. Ingber, Scott W. Andersen, Alette M. Wessels, Paul Ardayfio, Cynthia Evans, Stephen Salloway and Albert Lo. Their work appears in journals such as Alzheimer s & Dementia, Neurology, The Journal of Prevention of Alzheimer s Disease, Head & Neck and Alzheimer s & Dementia Translational Research & Clinical Interventions.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact